Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Mar 22, 2016 8:30 AM - Mar 23, 2016 4:30 PM

Medical Affairs and Scientific Communications 2016 Annual Forum Virtual Conference

Session 2: Demonstrating and Communicating the Value of Medicines Through Health Economic and Outcomes Evidence

Session Chair(s)

Donna  Wartski

Donna Wartski

Medical Outcomes Specialist

Pfizer, United States

Darryl  L'Heureux, PhD, MPharm, MSc

Darryl L'Heureux, PhD, MPharm, MSc

Director, Clinical Science, Medical Writing, and Publications

Ambrx, Inc, United States

The reimbursement landscape has elevated the importance of health economics and outcomes research (HEOR) within the pharmaceutical industry. Demands from payers, population health decision makers, and payment models that incentivize quality have placed higher demands on the data provided and the importance of market access. In addition to clinical attributes such as safety and efficacy, there is an increased demand for evidence supporting the real world use of a drug, including patient experience, medication adherence, comparative effectiveness, and cost implications. It is essential for medical communicators working on any HEOR-related work to understand the role of that work within the context of the value proposition. Furthermore, field medical colleagues such as medical liaisons and outcomes liaisons play an important role in communicating this information to payers to inform their formulary decisions and quality initiatives.

Learning Objective :
  • Review the external regulatory and health care landscape
  • Describe the scope of health pharmacoeconomic research and the differences from clinical trials
  • Discuss why health outcomes and pharmacoeconomics data are important to payer customers and how they use this information
  • Examine effective medical communication techniques and tools utilized by field medical colleagues

Speaker(s)

Eleni  Allen, PharmD

Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence

Eleni Allen, PharmD

Amgen Inc., United States

Senior Manager, REMS Program Management (RPM)

Christopher  Marrone, PharmD, RPh

Communicating the Value of Medicines to Payer Customers

Christopher Marrone, PharmD, RPh

Eli Lilly and Company, United States

Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)

Richard  Montgomery

Customer Insight

Richard Montgomery

Adventist Health System, United States

Contracts and Operations Manager- Pharmacy

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.